|
|
|
|
|
12.11.26 - 13:03
|
Bristol Myers Squibb Announces Evolution of Research & Development Organization (Business Wire)
|
|
|
Cristian Massacesi to Lead Unified R&D Organization Designed to Accelerate Pipeline Momentum, Effective January 1, 2027PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #Patients--Bristol Myers Squibb (NYSE: BMY) today announced that Cristian Massacesi will lead a unified, end-to-end Research & Development organization, effective January 1, 2027. As part of this planned transition, Robert Plenge will remain with Bristol Myers Squibb in an advisory capacity through March 2027 to support a seamless transition before departing the company.
“Bringing Research and Development together as one organization is an important step in our work to position BMS for long-term growth,” said Christopher Boerner, Ph.D., board chair and chief executive officer. “Under Cristian's leadership, this new structure will more closely connect our scientific and clinical expertise across R&D, accelerate decision making and ultimately enhance portfolio execution. Increasingly, traditional boundaries between research and development are c...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.10.26 - 12:30
|
Bristol Myers Squibb Co. Q3 Income Retreats (AFX)
|
|
|
NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb Co. (BMY) released a profit for third quarter that Drops, from the same period last yearThe company's bottom line totaled $2.162 billion, or $1.05 pe......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
